Trastuzumab - Biologic Drug Details

Summary for trastuzumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	6
BLAs:	7
Suppliers: see list	7
Recent Clinical Trials:	See clinical trials for trastuzumab

Recent Clinical Trials for trastuzumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Sarah Sammons, MD	PHASE1
Stemline Therapeutics, Inc.	PHASE1
Xijing Hospital	PHASE2

See all trastuzumab clinical trials

Pharmacology for trastuzumab

Mechanism of Action	HER2/Neu/cerbB2 Antagonists
Established Pharmacologic Class	HER2/neu Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for trastuzumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for trastuzumab Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for trastuzumab Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Trastuzumab

Last updated: March 28, 2026

What is the current state of the trastuzumab market?

Trastuzumab, marketed as Herceptin by Genentech/Roche, is a monoclonal antibody targeting HER2-positive breast cancer. Since its approval in 1998, it has maintained a leading position in breast cancer therapy. The global market size for trastuzumab was valued at approximately $7.2 billion in 2022 and is projected to grow at a CAGR of 8.5% through 2030, reaching around $14 billion.

Major factors include:

• Widespread adoption for early and advanced HER2-positive breast cancer.
• Expansion into gastric and gastroesophageal cancers.
• Competitive launches of biosimilars reducing prices and increasing accessibility.

How do biosimilars influence the market?

Biosimilars entered the market beginning in 2019, following patent expirations in 2018. Countries with strong biosimilar policies experienced substantial price reductions. For instance, in Europe, biosimilars have captured over 50% of the HER2-positive breast cancer market, reducing costs by approximately 30%.

Key biosimilar players include:

• Fresenius Kabi (Kix-derumab and other variants).
• Celltrion (Herzuma).
• Samsung Bioepis (Ontruzant).

By 2025, biosimilars are projected to account for up to 60% of the trastuzumab market, exerting downward pressure on revenue for originator (Herceptin).

What are the primary revenue drivers?

1. Indication expansion

   • HER2-positive breast cancer (early and metastatic stages).
   • Gastric and gastroesophageal cancers.
   • Ongoing trials for lung and other solid tumors.

2. Geographical growth

   • North America: Largest market, with a 40% share.
   • Asia-Pacific: Fastest growth, driven by emerging markets and increasing cancer incidence.

3. Pricing strategies

   • Introduction of biosimilars reduces prices.
   • Use of managed access programs to expand patient coverage.

4. Treatment guidelines

   • National guidelines increasingly recommend trastuzumab as first-line therapy, increasing demand.

What are the risks and uncertainties?

• Patent expiration for Herceptin in 2019 in the U.S. and EU, though patents for specific formulations and delivery devices extend beyond 2023.
• Regulatory hurdles slowing biosimilar adoption.
• Competition from newer agents like trastuzumab emtansine (Kadcyla) and trastuzumab deruxtecan (Enhertu) offering efficacy advantages in specific settings.
• Reimbursement policies vary geographically, influencing market penetration.

How does R&D influence future growth?

Research focuses on:

• Combining trastuzumab with immune checkpoint inhibitors.
• Developing subcutaneous formulations to improve patient convenience.
• Exploring new indications based on HER2 expression beyond breast and gastric cancers.

Phase III trials for combinations with PD-1/PD-L1 inhibitors show promise. These could extend the drug’s use, contributing to future revenue streams.

What financial forecasts are available?

Year	Estimated Market Size	Growth Rate	Major Revenue Contributors
2022	$7.2 billion	—	Early breast, gastric cancers
2025	$10.3 billion	8.5% CAGR	Biosimilar penetration, new indications
2030	$14 billion	8% CAGR	Expanded line of indications

Revenue is expected to stabilize as biosimilars gain market share but maintained by expanding indications and ongoing R&D.

What are the key competitive advantages and challenges?

Advantages:

• Proven efficacy and safety profile.
• Broad approval across multiple indications.
• Established manufacturing and distribution infrastructure.

Challenges:

• Evolving biosimilar landscape compresses profit margins.
• Competitive products with improved efficacy or safety profiles.
• Market saturation in high-income regions.

Key Takeaways

• The trastuzumab market is entering a period of substantial growth driven by biosimilar competition and indication expansion.
• Revenue is expected to peak around 2030, with biosimilars contributing to lower prices.
• R&D efforts focus on combination therapies and formulations to sustain growth.
• Regional disparities in adoption affect revenue trajectories.
• Patent cliffs in major markets, combined with regulatory and reimbursement hurdles, shape market dynamics.

FAQs

1. When will biosimilars significantly impact trastuzumab revenues?
Biosimilars entered markets globally starting in 2019; by 2025, they are anticipated to account for over 60% of the market, substantially reducing originator revenues.

2. Which regions are seeing the fastest growth for trastuzumab?
Asia-Pacific demonstrates the highest compound annual growth, owing to rising cancer prevalence and expanding healthcare infrastructure.

3. What upcoming indications could drive future revenue?
Clinical trials are exploring HER2 targeting in lung, colorectal, and other solid tumors, which could expand the drug’s indications.

4. How do new formulations influence market share?
Subcutaneous formulations improve patient convenience, providing competitive advantages over intravenous options and potentially capturing additional market share.

5. What regulatory factors could affect the market?
Stringent approval processes for biosimilars and varying reimbursement policies influence market penetration and revenue potential.

References

[1] Grand View Research. (2022). Trastuzumab Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Global Oncology Biosimilars Outlook.
[3] European Medicines Agency. (2023). Guidelines on Biosimilar Development and Approval.
[4] Miller, K. et al. (2023). Trends in HER2-targeted therapies. Journal of Oncology.
[5] Statista. (2023). Global Oncology Market Revenue Forecast.